CENT[©]GENE

The Essential Life Science Partner for Data-Driven Answers in Rare & Neurodegenerative Diseases

CENTOGENE (CNTG) Company Presentation January 2023

Disclaimer

This presentation has been prepared by CENTOGENE N.V. (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology, such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project" or "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage growth and enter into new client relationships, our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements are subject of

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2021, on Form 20-F filed with the SEC on March 31, 2022, and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CENTOGENE @ a glance



- Headquarters **Rostock, Germany**, with locations in **Boston, MA**, **Berlin, Germany**, **Belgrade, Serbia**, and **Rotkreuz, Switzerland**
- ~420 employees¹
- Listed on **Nasdaq** in November 2019 (Ticker: CNTG)



- FY2021 revenues of €42.3 million²
- Guidance³ FY2022:
 - Revenues of ~ €46.5 €48.2 million
 YoY growth 9-13%




- CENTOGENE Biodatabank, the world's largest real-world data repository for rare and neurodegenerative diseases
- State-of-the-art genomics and multiomics reference lab (ISO, CAP, & CLIA certified)




- >50 collaborations with biotech/biopharma partners, covering over 46 rare diseases⁴
- Market access and expansion, clinical development, target and drug screening

3 1 Based on FTE basis per 2022, excl. consultants, interns, long-term leavers (maternity, sick leave, ...).² Prior year financials as revised per H1 2022 results filing on Dec 22, 2022 (unaudited and unreviewed). As of Q1 2022, the Company reported COVID-19 testing as discontinued operations. I.e. FY2021 only reflects revenues from the Company's Diagnostics & Pharma segments. The COVID-19 testing business was exited end of Q1 2022.³ Guidance as communicated per H1 2022 earnings announcement on Dec 22, 2022. ⁴ Reflecting total, not related to current reporting period only

Essential Life Science Partner for Data-Driven Answers in Rare and Neurodegenerative Diseases



Insights into 2,500 rare and neurodegenerative diseases to support breakthrough therapies



The Opportunity: By 2024, 18% of Rx Worldwide Expected to Target Rare Diseases

Significant Need Rare Diseases	 ~350 million people affected by rare genetic diseases, ~90% undiagnosed Estimated 80% of ~7,000 rare diseases are genetic in origin: ~5,600¹ Public datasets are ~80% of European descent⁷ <5% of rare diseases have meaningful therapies
Growing Market for Rare Rx	 Rare diseases market expected to grow 11+% to 2024³ By 2024, rare disease products expected ~18% R sales⁴ FDA have approved 23 gene/cell therapies to date⁵ >50% of FDA approvals in 2021 were orphan drugs⁶
Stakeholder Pressure to Act	 Regulatory/payor scrutiny raises standards for approval, access, and entry Patient engagement for new RD, NDD, & gene therapies; even with premium priced products Stratification and patient profiling can improve labelling, pricing optimization and success

6 1 Compare Centogene 20-F for FY2021 p. 56 I 2 CENTOGENE Biodatabank statistic per Dec 31, 2021. I 3 & 4 EvaluatePharma – Orphan Drug Report 2020 p. 2 I 5 Based on FDA approvals per May 2022. [Approved Cellular and Gene Therapy Products IEDA] I 6 EvaluatePharma – Orphan Drug Report 2022 p. 2 I 7 The Scientist (2019) "Lack of Diversity in Genetic Datasets is Risky for Treating Disease", reflecting distribution of ancestry of individuals in genome-wide association studies (GWAS) as of January 2019 I * Statements reflect internal management estimates.

Near-term opportunities in addressing key stakeholder challenges

Patients, Patient Groups, Disease Foundations

STAKEHOLDER NEEDS

Healthcare Providers, Payors

• **Diagnosis** faster than 7yr average wait

- Acceleration / de-risking of clinical development stages
- Access to relevant data and patients
- Prove of efficacy to payors & regulators
- Predictability of treatment success
- Efficacy-based pricing

Biopharma, CROs, Al **Physicians**


Authorities: FDA, EMA

Our ambition is to be the essential life science partner for data-driven in rare and neurodegenerative diseases

Fueling revenues, growing CENTOGENE Biodatabank, and building pharma partnerships




CENTOGENE Biodatabank: Highly diverse real-world data repository for rare and neurodegenerative diseases



9 Metrics per July, 2022. Active Physicians defined as contact with CENTOGENE within the last 5 years, respectively.

The breadth and depth of the CENTOGENE Biodatabank makes it a unique resource



>400,000 biosamples from>120 countries

~30,000 active physicians in our network

~50% broad research consent
(>70% in recent years)

High diversity in geographies, ethnicities and patient characteristics Country represented in Biodatabank Country not represented in Biodatabank

>70% of individuals of noneuropean descent*

>31 million unique variants


High share of pediatric cases
13k families with trio analysis

>2,500 rare diseases covered with diagnosed patients

Clinical Diagnostics Market Access & Expansion Clin. Development Support Target & Drug Screening

Metrics per July, 2022. Active defined as contact with CENTOGENE within the last 5 years, respectively. * Internal estimate.


First-in-class data capture and proprietary curation and analysis technologies




Value chain supported by advanced bioinformatics and AI tools



Diagnostics: A distinctive offering and services that support efficient and timely diagnosis of rare and neurodegenerative diseases, leading to better treatment and health outcomes



CENTOGENE Unique Pharma Offering: Our ambition is to be the essential life science partner for data-driven answers in rare and neurodegenerative diseases



Market Access and Expansion: Maximize access and personalize patient, provider, and pharma value

Market Access and Expansion

- Real world registry
- Early access programs
- Patient Stratification
- Genetic and Biomarker Profiling
- Modelling
- Patient Identification
- Patient Diagnostics
- CENTOGENE Biodata Network
 - Insight Reports & CNTG Biodatabank
 Licenses



- 2015 Ongoing
- Rare metabolic and rare neurodegenerative diseases
- Provide diagnostic testing services to identify patients with rare metabolic and rare neurodegenerative diseases
- 42 Countries



- 2015 Ongoing
- Hereditary transthyretin amyloidosis (hATTR) disease
- Sponsored testing program with > 600 samples from 10 countries (Europe) & 125 samples (U.S.)



• 2019 - 2022

- Duchenne muscular dystrophy (DMD)
- DMD Sponsored testing program (250 samples)
- 5 countries: UAE, KSA, Lebanon, Kuwait, Egypt



- 2019 Ongoing
- Identify patients in **DMD &** Aromatic L-amino Acid Decarboxylase (**AADC**)
- Genetic testing and biomarker analytics for AADC deficiency in 65 countries (LATAM, Europe, MENA)
- >2,500 DMD & >2,900 AADC samples screened

Clinical Development: Accelerate and expand pharma partnerships

Clinical Development

Observational studies

- Epidemiology & Patient finding
- Genetic & biomarker
 profiling

POC/Ph II/III

- Patient multiomic profiling
- Stratification, Modelling, and Efficacy markers
- Patient identification & diagnostics

CENTOGENE Biodata Network

 Insight Reports & CNTG Biodatabank Licenses

• 2021

- Hypophosphatasia (HPP)
- Strensiq (innovative enzyme replacement therapy)
- De novo variant identification for HPP and identification of potential new genes causing HPP
- Germany

ᠵ agios

- 2021 Ongoing
- Pyruvate kinase ("PK") deficiency
- Genetic testing and identification of causative mutations, incl. HBA1, HBA2, and HBB genes, in Ph. II/III trials
- 20 Countries (North America, Europe, MENA, APAC, & LATAM)

- 2018 Ongoing (ROPAD Study with extensions)
- Parkinson's disease (PD)
- Enroll and genotype 12,500 patients
- 10 countries

Alnylam

Germany

• 2020 - Ongoing

amyloidosis (hATTR)

5,000 patients enrolled

• Recently extended to test 5,000 patients more

Hereditary transthyretin-related

· Longitudinal study providing a

hATTR via NGS and MLPA

molecular genetic diagnosis of



- 2018 2021
- Gaucher disease
- Longitudinal natural history study (LysoProof) with >1,600 samples analyzed
- **13 countries** (EU, LATAM, APAC, MENA)
- Identified and genetically tested
 >250 Gaucher patients

alector

- 2021 Ongoing
- Frontotemporal dementia (FTD)
- Enroll and genetically test over 3,000 FTD patients in EFRONT Study
- 7 countries (Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey)

Target & Drug Screening: Build partnerships around precision and confidence

Target and Drug Screening

Target & Drug Screening

- Patient-derived cell models & multiomics
- Biomarker/Assay identification & validation

CENTOGENE Biodata Network

 Insight Reports & CNTG **Biodatabank Licenses**





- 2021 Ongoing
- Niemann-Pick type C
- Collaboration to generate data set to enable start of drug discovery

CENT©GENE

- 2021 Ongoing
- Friedreich's Ataxia, Duchenne Muscular Dystrophy, Hereditary transthyretin-related amyloidosis
- Novel biomarker discovery to stratify and monitor patients for disease severity/progression and to enable the discovery of disease modifiers explaining heterogeneity

CENT©GENE



• 2020 - Ongoing


- Gaucher Disease joint drug discovery project
- Joint drug discovery project to identify small molecules reducing biomarker Lyso-GB1 in disease cell models
- Transcriptomic and metabolomic data set enabling patient selection with highest unmet need



- 2018 2022
- Rare neurodegenerative diseases
- Data Access and Collaboration Agreement granting access to the CENTOGENE Biodatabank for discovery & validation of novel genetic and biochemical targets for the potential development of new therapies for rare diseases

CENTOGENE Financials – per H1 2022

Core Business - Dx and Biopharma revenues¹



Diagnostics

- H1' 22 revenues of 14.5 € million +15% vs H1'21
- # tests for Whole Exome/ Genome Sequencing (WES/ WGS) up 34.7% YoY
- Received CE-mark for CentoCloud decentralized SaaS and clinical decision support platforms

Recovering from COVID impact

Outgrowing the market

Biopharma

- H1' 22 revenues of 6.9 € million +7% vs H1'21
- Increased activity in the clinical studies of pharmaceutical partners
- 45 active collaborations; 12 contracts signed in H1'22; there/of 10 with existing partners
- Launched Biodata Network data-driven partnering solutions for biopharma and research

^{17 1.} In EUR million, rounded, graph not drawn to scale. Core Business defined as revenue from the Diagnostics and Pharma reporting segments, excludes COVID-19 testing. Prior period financials as revised per H1 2022 results filing on Dec 22, 2022 (unaudited and unreviewed). Guidance as communicated per H1 2022 earnings announcement on Dec 22, 2022, bar chart reflects midpoint

Near- and mid-term priorities

Growth

- Focus on unique and transformative business model
- Expand pharma partnerships
 - Fully execute on our ongoing partnerships and target ~20+ new pipeline deals
- Keep growing Dx at above-market level
 - Focus on profitable growth
 - Commercial excellence, CentoCloud, & multiomics

Cost management

- Drive fit-for-purpose organization
- Focus on efficient operations and margin improvement

Cashflow

18

- Sector is not about growth at all costs
- Diligently manage cash and extend runway



Bottomline

Topline



ŀ	-	1	
2	202	22	

Revenues of €21.4M up +13% yoy driven by Diagnostics +15% yoy and Pharma +7% yoy



~\$62M financing (~€55M) in Q1 2022: €15M PIPE & \$45M secured debt facility **

* Revenues reflect the Diagnostics and Pharma reporting segments, and do not include the COVID-19 Testing revenues recorded in the period 2020 – Q1 2022. COVID-19 Testing has been reported as discontinued operations since Q1 2022. Prior period financials as revised per H1 2022 results filing on Dec 22, 2022 (unaudited and unreviewed). Guidance as communicated per H1 2022 earnings announcement on Dec 22, 2022. ** CENTOGENE announced the closing of a € 15 million (~\$ 17 million per USD/EUR Fx rate at that time) private placement financing incl. warrants as well as the entry into a USD 45 million senior secured loan facility on February 1, 2022. / Image source: flaticon.com

CENT[©]GENE

Thank you